Zimmer Biomet Holdings, Inc.
ZBHHealthcareNASDAQMedical Devices · Last scanned Oct 26, 2026
Scan Results
Daily timeframeZimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The $18.80B market capitalization puts ZBH squarely in large-cap range for its industry. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T.
Market Cap
$18.80B
Beta
0.48
P/E (TTM)
23.92
P/E (Fwd)
10.87
EPS (TTM)
$4.12
EPS (Fwd)
$9.07
ROE
6.4%
ROA
3.9%
Cash
$464.5M
Total Debt
$7.60B
Free CF
$1.07B
52W Change
-4.4%
Annual Financials
Cash vs Debt
Where ZBH stands vs its 150-day and 200-day moving averages
As of the October 15, 2026 close, ZBH finished 1.19% above its 150-day moving average ($90.69) and 0.96% above its 200-day moving average ($90.90). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ZBH overbought or oversold?
At the October 15, 2026 close, ZBH's RSI(14) was 57.3, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Zimmer Biomet Holdings, Inc. carries $7.60B in total debt against $464.5M in cash reserves — debt is roughly 16.4x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $1.07B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 6.4% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 3.9% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $6.94B to $8.23B.
With a beta below 0.7, Zimmer Biomet Holdings, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ZBH.